Evaluating the conversion to extended-release tacrolimus from immediate-release tacrolimus in liver transplant recipients.

Background: A new formulation of once daily extended-release tacrolimus (LCP-tac, Envarsus XR) was approved for use in the USA for kidney transplant recipients in 2015. There are limited data regarding real-world observations with conversion to LCP-tac in liver transplant recipients.

Methods: We performed a retrospective analysis of liver transplant recipients treated with LCP-tac.